Details of Disease

General Information of Disease (ID: DISA6W3T)

Disease Name	Gallbladder disease
Synonyms	gallbladder disorder; gall bladder disease or disorder; disease or disorder of gall bladder; disorder of gall bladder; disease of gall bladder; gall bladder disease; Gall bladder disorder
Disease Class	DC11: Cholelithiasis
Definition	A disease involving the gall bladder.
Disease Hierarchy	DISEW817: Hepatobiliary disorder DISWD40R: Disease DISA6W3T: Gallbladder disease
ICD Code	ICD-11 ICD-11: DC11.3 ICD-10 ICD-10: K80-K87 Expand ICD-11 'DC1Z Expand ICD-10 'K80-K87
Disease Identifiers	MONDO ID MONDO_0005281 MESH ID D005705 UMLS CUI C0016977 MedGen ID 8947 SNOMED CT ID 39621005

Drug-Interaction Atlas (DIA) of This Disease

Drug-Interaction Atlas (DIA)

This Disease is Treated as An Indication in 2 Approved Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
Iodipamide	DMXIQYS	Approved	Small molecular drug	[1]
Tyropanoate sodium	DM326CN	Approved	Small molecular drug	[2]
------------------------------------------------------------------------------------

This Disease is Treated as An Indication in 1 Clinical Trial Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
PEGPH20	DM26YJ1	Phase 2	NA	[3]
------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA) of This Disease

Molecular Interaction Atlas (MIA)

This Disease Is Related to 5 DTT Molecule(s)

Gene Name	DTT ID	Evidence Level	Mode of Inheritance	REF
ABCB4	TTJUXV6	Strong	Genetic Variation	[4]
ABCG5	TTKZ7WY	Strong	Genetic Variation	[5]
APOB	TTN1IE2	Strong	Genetic Variation	[6]
GLP2R	TT1YWO5	Strong	Biomarker	[7]
PDK3	TTDEQIP	Strong	Altered Expression	[8]
------------------------------------------------------------------------------------

This Disease Is Related to 7 DOT Molecule(s)

Gene Name	DOT ID	Evidence Level	Mode of Inheritance	REF
ABCG8	OTIJ76XW	Strong	Genetic Variation	[5]
CDO1	OTLG1P77	Strong	Posttranslational Modification	[9]
EBAG9	OTTQLQCP	Strong	Altered Expression	[10]
GP2	OTB6TMGY	Strong	Biomarker	[11]
HOXD9	OTZ4GVR1	Strong	Altered Expression	[12]
OPCML	OT93PQ6Y	Strong	Altered Expression	[12]
TTC39B	OTE2ZGFB	Strong	Genetic Variation	[5]
------------------------------------------------------------------------------------


⏷ Show the Full List of 7 DOT(s)

References

1	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7400).
2	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
3	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
4	Comparison of in silico prediction and experimental assessment of ABCB4 variants identified in patients with biliary diseases.Int J Biochem Cell Biol. 2017 Aug;89:101-109. doi: 10.1016/j.biocel.2017.05.028. Epub 2017 Jun 3.
5	Lipids, obesity and gallbladder disease in women: insights from genetic studies using the cardiovascular gene-centric 50K SNP array.Eur J Hum Genet. 2016 Jan;24(1):106-12. doi: 10.1038/ejhg.2015.63. Epub 2015 Apr 29.
6	Apolipoprotein B (APOB) gene polymorphism in patients with gallbladder disease.Arch Med Res. 2007 Apr;38(3):360-3. doi: 10.1016/j.arcmed.2006.11.003.
7	New Avenues in the Regulation of Gallbladder Motility-Implications for the Use of Glucagon-Like Peptide-Derived Drugs.J Clin Endocrinol Metab. 2019 Jul 1;104(7):2463-2472. doi: 10.1210/jc.2018-01008.
8	Serum pyruvate dehydrogenase kinase as a prognostic marker for cholangiocarcinoma.Oncol Lett. 2019 Jun;17(6):5275-5282. doi: 10.3892/ol.2019.10185. Epub 2019 Mar 22.
9	Prognostic significance of promoter DNA hypermethylation of the cysteine dioxygenase 1 (CDO1) gene in primary gallbladder cancer and gallbladder disease.PLoS One. 2017 Nov 21;12(11):e0188178. doi: 10.1371/journal.pone.0188178. eCollection 2017.
10	The tumor-associated antigen, RCAS1, can be expressed in immune-mediated diseases as well as in carcinomas of biliary tract.J Hepatol. 2002 Jun;36(6):786-92. doi: 10.1016/s0168-8278(02)00066-1.
11	Serological diagnosis and prognosis of severe acute pancreatitis by analysis of serum glycoprotein 2.Clin Chem Lab Med. 2017 May 1;55(6):854-864. doi: 10.1515/cclm-2016-0797.
12	Serum cell-free DNA methylation of OPCML and HOXD9 as a biomarker that may aid in differential diagnosis between cholangiocarcinoma and other biliary diseases.Clin Epigenetics. 2019 Mar 4;11(1):39. doi: 10.1186/s13148-019-0634-0.